miR‑361 enhances sensitivity to 5‑fluorouracil by targeting the FOXM1‑ABCC5/10 signaling pathway in colorectal cancer
- Luyao Zhang
- Bo Li
- Beilin Zhang
- Hua Zhang
- Jian Suo
Affiliations: Department of Gastrointestinal Surgery, First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Gastrointestinal Surgery, The Third Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Physiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China
- Published online on: August 14, 2019 https://doi.org/10.3892/ol.2019.10741
Copyright: © Zhang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Colorectal cancer (CRC) is one of most common malignancies worldwide. 5‑fluorouracil (5‑FU) is a mainstay of CRC treatment, particularly in patients with advanced stages of the disease; however, 5‑FU‑based chemotherapy is not always effective and may result in progression of the disease. The present study investigated several candidate microRNAs (miRs) in parental and 5‑FU‑resistant HCT116 and HT29 cells, and identified miR‑361 as a novel regulator of chemosensitivity. Overexpression of miR‑361 enhanced the 5‑FU susceptibility of parental and resistant HCT116 and HT29 cells in vitro. Impaired colony formation capacity and increased cell apoptosis (as determined via flow cytometry) was observed in resistant HCT116 and HT29 cells. Furthermore, forkhead box M1 (FOXM1) was identified as a target gene of miR‑361 using a dual‑luciferase reporter assay, western blotting and reverse transcription‑quantitative PCR. Additionally, FOXM1 knockdown improved the cytotoxicity of 5‑FU in resistant CRC. ATP binding cassette subfamily C members 5 and 10 (ABCC5/10) were found to be downstream effectors of miR‑361. In conclusion, miR‑361 increased chemosensitivity, at least in part, via modulation of FOXM1‑ABCC5/10. miR‑361 may serve as a potential therapeutic target for patients with CRC.